Comparison of an evidence-based and a conventional mastitis therapy concept with regard to cure rates and antibiotic usage


  • Elisabeth Maria Mansion-de Vries
  • Johanna Lücking
  • Nicole Wente
  • Claudia Zinke
  • Martina Hoedemaker
  • Volker Krömker


evidence-based mastitis therapy, clinical cure


In milk production, mastitis therapy accounts for the largest proportion of antibiotic use. Numerous studies have suggested that with a differentiated therapy based on mastitis causing pathogens and animal individual variables (regarding the number of lactation, somatic cell count (SCC) and the number of pre-treatments) the amount of antibiotics could be significantly lowered.
The aim of this study was to investigate whether the establishment of an evidence-based mastitis therapy (EBMT) concept could reduce the amount of applied antibiotics compared to a conventional therapeutic (CT) approach with similar curing success. In the EBMT concept the therapy is tailored - with the additional help of on farm culture in the form of PetrifilmsTM - to the pathogen and to the patient and includes the latest scientific knowledge. In the CT approach the therapy is only
tailored to the patient. The decision concerning therapy depends basically on the knowledge of the therapist and the severity of mastitis symptoms.
To this end, from February until December 2012 all of the approximately 950 cows on a conventional dairy farm in Saxony-Anhalt, Germany, with clinical mastitis cases were assigned to an EBMT- (n = 236 cows) and a CT-group (n = 230 cows) based on the ear tag number and treated accordingly. Subsequently, the results of the two treatment groups were evaluated with respect to the clinical cure (CC), the bacteriological cure (BC), the full cure (FC), the relapse and culling rate and the amount of local and parenteral antibiotics used. Furthermore, the mean costs per clinical mastitis case of these two therapeutic concepts were compared.
There was a significantly higher CC in the EBMT- versus the CT-group with simultaneous significant reduction in the local antibiotic doses without negative influence on the BC, FC, relapse and culling in the EBMT-group. Also, the mean costs per clinical mastitis case were significantly lower in the EBMT-group.
This pilot study showed that by implementing on farm culture the use of an EBMT concept significantly reduces the use of local antibiotics in mastitis therapy without having any negative significant changes in the therapy outcome or economic aspects.


Neeser NL, Hueston WD, Godden SM, Bey RF. Evaluation of the use of an on-farm system for bacteriologic culture of milk from cows with low-grade mastitis. J Am Vet Med Assoc. 2006; 228: 254-60.

Roberson JR, LD Warnick, G Moore. Mild to moderate clinical mastitis: Efficacy of intramammary amoxicillin, frequent milk-out, a combined intramammary amoxicillin, and frequent milk-out treatment versus no treatment. J Dairy Sci. 2004; 87: 583-592.

Pyörälä SH, EO Pyörälä. Efficacy of parenteral administration of three antimicrobial agents in treatment of clinical mastitis in lactating cows: 487 cases. J Am Vet Med Ass. 1998; 212: 407-412.

Erskine RJ, PC Bartlett, JL Van Lente, CR Phipps. Efficacy of systemic ceftiofur as a therapy for severe clinical mastitis in dairy cattle. J Dairy Sci. 2002; 85: 2571-2575.

Krömker V, JH Paduch, D Klocke, J Friedrich, C Zinke. Wirksamkeit einer verlängerten Arzneimittelapplikation zur Behandlung mittel- hochgradiger klinischer Mastitiden bei Milchkühen. Ber Münch Tierärztl Wochenschr. 2010; 123: 147-152.

Guterbock WM, AL Van Eeenennaam, RJ Anderson, IA Gardner, JS Cullor, CA Holmberg. Efficacy of intramammary antibiotic therapy for treatment of clinical mastitis caused by environmental pathogens. J Dairy Sci. 1993; 76: 3437-3444.

Pyörälä S, L Kaartinen, H Käck. Efficacy of two therapy regimens for treatment of experimentally induced Escherichia coli mastitis in cows. J Dairy Sci. 1994; 77: 453-461.

Suojala L, H Simojoki, K Mustonen, L Kaartinen, S Pyörälä. Efficacy of enrofloxacin in the treatment of naturally occurring acute clinical Escherichia coli mastitis. J Dairy Sci. 2010; 93: 1960-1969.

Hillerton JE, KE Kliem. Effective treatment of Streptococcus uberis clinical mastitis to minimize the use of antibiotics. J Dairy Sci. 2002; 85: 1009-1016.

Wenz JR, GM Barrington, FB Garry, KD McSweeney, RP Dinsmore, G Goodell, RJ Callan. Bacteremia associated with naturally occurring acute coliform mastitis in dairy cows. J Am Vet Med Assoc. 2001; 219: 976-981.

Sol J, OC Sampimon, HW Barkema, YH Schukken. Factors associated with cure after therapy of clinical mastitis caused by Staphylococcus aureus. J Dairy Sci. 2000; 83: 278-284.

Pinzón-Sánchez C, PL Ruegg. Risk factors associated with shortterm post-treatment outcomes of clinical mastitis. J Dairy Sci. 2011; 94: 3397-3410.

Sackett DL, WM Rosenberg, JA Muir-Gray, RB Haynes. Evidence based medicine: what it is and what it isn’t. Brit Med J. 1996; 312: 71-72.

International Dairy Federation (IDF). Suggested interpretation of mastitis terminology. Bulletin of the IDF. 1999; 338, Brussels.

German Veterinary Association (GVA). Guidelines for antiseptic milk sampling and guidelines to isolate and identify mastitis pathogens. GVA. 2009; Gießen, Germany. [Deutsche Veterinärmedizinische Gesellschaft (DVG). Leitlinien zur Entnahme von Milchproben unter antiseptischen Bedingungen und Leitlinien zur Isolierung und Identifizierung von Mastitiserregern. GVA. 2009; Gießen, Deutschland.]

National Mastitis Council (NMC). Laboratory Handbook on Bovine Mastitis. NMC. 1999; Madison, WI.

Mansion-de Vries EM, N Knorr, JH Paduch, C Zinke, M Hoedemaker, V Krömker. A field study evaluation of Petrifilm™ plates as a 24-h rapid diagnostic test for clinical mastitis on a dairy farm. Prev Vet Med. 2014; 113(4): 620-624.

McCarron J, G Keefe, S McKenna, I Dohoo, D Poole. Laboratory evaluation of 3M Petrifilms and University of Minnesota Bi-Plates as potential on-farm tests for clinical mastitis. J Dairy Sci. 2009; 92: 2297-2305.

Owens WE, SC Nickerson, CH Ray. Efficacy of parenterally or intramammarily administered tilmicosin or ceftiofur against Staphylococcus aureus mastitis during lactation. J Dairy Sci. 1999; 82: 645-647.

Østerås O. Mastitis epidermiology - Practical approaches and applications. 24. World Buiatrics Congress. 2006; Nizza: 203-215.

Shpigel NY, M Winkler, A Saran, G Ziv, F Longo. Anti-inflammatory ketoprofen in the treatment of field cases of bovine mastitis. Res Vet Sci. 1994; 56: 62-68.